Completed PHASE4 INTERVENTIONAL 1-arm NCT00806494

UK Study Assessing Flexible Dose Fesoterodine in Adults (SAFINA)

A 12 Week, Multi-centre, Open Label Study To Evaluate The Efficacy, Tolerability And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.

Sponsor: Pfizer

Conditions Urinary Bladder, Overactive

Interventions Fesoterodine

Updated 8 times since 2017 Last updated: Jan 4, 2011 Started: Feb 28, 2009 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Urinary Bladder, Overactive, this trial is completed. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Addlestone, United Kingdom , Ashford, United Kingdom , Ayrshire, United Kingdom , Baillieston, United Kingdom , Bath, United Kingdom , Bexhill-on-Sea, United Kingdom , Blackpool, United Kingdom , Bradford-on-Avon, United Kingdom , Bristol, United Kingdom , Bucks, United Kingdom and 23 more locations